Your session is about to expire
← Back to Search
SGLT2-Inhibitors for Sleep Apnea in Heart Failure
Study Summary
This trial is investigating whether a new drug class called Sodium glucose co-transporter 2 (SGLT2)-Inhibitors can help in the treatment of sleep disordered breathing.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 30 Patients • NCT03006471Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can safely take dapagliflozin without health risks.I am an adult who can legally consent.I have been diagnosed with sleep-disordered breathing.I do not have heart failure.I have been diagnosed with heart failure.I cannot take dapagliflozin due to severe kidney issues or past severe low blood sugar episodes.I do not have sleep-disordered breathing.
- Group 1: SGLT2-SDB
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical conditions does Dapagliflozin commonly target?
"Dapagliflozin is effective in managing pharmaceutical preparations, diet, and exercise."
Is it possible to still sign up for this clinical trial?
"This particular trial is not recruiting patients at the moment, as noted by the last update to the listing on 3/8/2022. However, there are 1091 trials for heart failure and 67 studies involving Dapagliflozin that are actively seeking candidates."
When was Dapagliflozin cleared by the FDA for public use?
"Dapagliflozin's safety is based on phase 2 trial data, meaning that while there is some evidence backing its safety, none exists yet for its efficacy."
Is this a groundbreaking medical study?
"There are 67 ongoing clinical trials worldwide for the medication dapagliflozin. The first study was conducted in 2014 by AstraZeneca and completed the N/A drug approval stage with 700 patients. In the 6 years since, 175 more studies have completed."
How many people are currently enrolled in this experiment?
"This study is no longer recruiting patients for participation. The trial was first posted on 4/1/2022 and ended recruitment on 3/8/2022. However, there are other ongoing studies that may be of interest. There are 1091 clinical trials actively searching for patients with heart failure and 67 studies for Dapagliflozin that are still recruiting participants."
Share this study with friends
Copy Link
Messenger